MDXH MDXHEALTH

Mdxhealth to Present at Upcoming Investor Conferences

Mdxhealth to Present at Upcoming Investor Conferences

       

Mdxhealth to Present at Upcoming Investor Conferences

IRVINE, CA, and HERSTAL, BELGIUM – May 15, 2024 () – Mdxhealth SA (Nasdaq: MDXH), a commercial-stage precision diagnostics company, today announced that Michael K. McGarrity, Chief Executive Officer, will participate in the following investor conferences in June 2024.

William Blair 44th Annual Growth Stock Conference

Presentation: Wednesday, June 5, at 5:00pm ET

Webcast:

Jefferies Global Healthcare Conference

Presentation: Thursday, June 6, at 1:30pm ET

Webcast:

Live webcasts of the presentations will be accessible on the Investor page of mdxhealth’s website at . Replays will be available for up to 60 days following each event.

About mdxhealth®

Mdxhealth is a commercial-stage precision diagnostics company that provides actionable molecular information to personalize patient diagnosis and treatment. The Company’s tests are based on proprietary genomic, epigenetic (methylation) and other molecular technologies and assist physicians with the diagnosis and prognosis of urologic cancers and other urologic diseases. The Company’s U.S. headquarters and laboratory operations are in Irvine, California, with additional laboratory operations in Plano, Texas. European headquarters are in Herstal, Belgium, with laboratory operations in Nijmegen, The Netherlands. For more information, visit mdxhealth.com and follow us on social media at: twitter.com/mdxhealth, facebook.com/mdxhealth and linkedin.com/company/mdxhealth.

For more information:

mdxhealth







 
LifeSci Advisors (IR & PR)

US:

 

NOTE: The mdxhealth logo, mdxhealth, Confirm mdx, Select mdx, Resolve mdx, Genomic Prostate Score, GPS and Monitor mdx are trademarks or registered trademarks of MDxHealth SA. All other trademarks and service marks are the property of their respective owners.

 

Attachment



EN
15/05/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on MDXHEALTH

Guy Sips ... (+7)
  • Guy Sips
  • Hilde Van Boxstael
  • Livio Luyten
  • Mathijs Geerts Danau
  • Michiel Declercq
  • Wim Hoste
  • Wim Lewi

Morning Notes : ACKB BB, FAGR BB, FUR NA, MTLS US, MDXH BB, PROX BB, R...

: ACKB BB, FAGR BB, FUR NA, MTLS US, MDXH BB, PROX BB, RECT BB, WHATS BB

Mathijs Geerts Danau
  • Mathijs Geerts Danau

mdxhealth FY25 revenues slightly below preliminary figures but guidanc...

mdxhealth's 4Q25 revenues come in $ 1m lower than the preliminary revenue figures shared in January ($ 30.5m). However the company maintains FY26 revenue guidance of $ 137-140m, implying 27-30% year-over-year revenue growth in FY26. Management also reiterated expectations for continued operating leverage, with a limited increase in OPEX despite significant revenue growth. As a result, mdxhealth expects to achieve a 10% adj. EBITDA run-rate by YE26. We reiterate our BUY and $ 6 TP.

 PRESS RELEASE

Mdxhealth Announces Fourth Quarter and Full-Year 2025 Financial Result...

Mdxhealth Announces Fourth Quarter and Full-Year 2025 Financial Results Mdxhealth Announces Fourth Quarter and Full-Year 2025 Financial Results Fourth quarter revenue growth of 19% to $29.5 million2025 revenue growth of 20% to $107.9 millionConference call with Q&A today at 4:30 PM EST / 22:30 CET IRVINE, California – February 26, 2026 () – MDxHealth SA (NASDAQ: MDXH) (the "Company" or "mdxhealth"), a leader in urology-focused precision diagnostics, today announced its financial results for the fourth quarter and year ended December 31, 2025. Michael K. McGarrity, CEO of mdxhealth, comme...

Guy Sips ... (+3)
  • Guy Sips
  • Mathijs Geerts Danau
  • Wim Hoste
Mathijs Geerts Danau
  • Mathijs Geerts Danau

mdxhealth ExoDx boosts 2026 growth expectations

Following mdxhealth preliminary 2025 full-year sales and 2026 sales guidance in the $ 137-140m range, we update our model and raise 2026 revenue estimates to $ 139.9m, driven by ExoDx and synergy potential with the GPS test. The ExoDx acquisition should ensure the company's high growth profile, and the increased scale should allow for further operational leverage. That said, we note that the company will likely require additional funding to cover cash outflow obligations. Given the high growth o...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch